<h1>Paper Summary</h1>

<!--META_START-->

<p>Title: An Age-Based Framework for Evaluating Genome-Scale Sequencing Results in Newborn Screening  </p>

<p>Authors: Laura V. Milko, Julianne M. O’Daniel, Daniela M. DeCristo, Stephanie B. Crowley, Ann Katherine M. Foreman, Kathleen E. Wallace, Lonna F. Mollison, Natasha T. Strande, Zahra S. Girnary, Lacey J. Boshe, Arthur S. Aylsworth, Muge Gucsavas-Calikoglu, Dianne M. Frazier, Neeta L. Vora, Myra I. Roche, Bradford C. Powell, Cynthia M. Powell, Jonathan S. Berg  </p>

<p>DOI: https://doi.org/10.1016/j.jpeds.2018.12.027  </p>

<p>Year: 2019  </p>

<p>Publication Type: Journal Article  </p>

<p>Discipline/Domain: Medical Genetics, Pediatrics, Genomic Medicine  </p>

<p>Subdomain/Topic: Newborn Screening, Clinical Actionability, Next-Generation Sequencing (NGS)  </p>

<p>Eligibility: Eligible  </p>

<p>Overall Relevance Score: 95  </p>

<p>Operationalization Score: 90  </p>

<p>Contains Definition of Actionability: Yes (explicit and implicit)  </p>

<p>Contains Systematic Features/Dimensions: Yes  </p>

<p>Contains Explainability: Yes  </p>

<p>Contains Interpretability: Partial  </p>

<p>Contains Framework/Model: Yes (ASQM – Age-based Semiquantitative Metric)  </p>

<p>Operationalization Present: Yes  </p>

<p>Primary Methodology: Conceptual + Comparative Validation Study  </p>

<p>Study Context: Evaluation of gene–disease pairs for genomic newborn screening using a standardized actionability metric  </p>

<p>Geographic/Institutional Context: North Carolina, USA; University of North Carolina at Chapel Hill  </p>

<p>Target Users/Stakeholders: Policy-makers, clinicians, genetic counselors, parents, newborn screening programs  </p>

<p>Primary Contribution Type: Conceptual framework with validation against existing panels  </p>

<p>CL: Yes  </p>

<p>CR: Yes  </p>

<p>FE: Yes  </p>

<p>TI: Partial  </p>

<p>EX: Yes  </p>

<p>GA: Partial  </p>

<p>Reason if Not Eligible: N/A  </p>

<!--META_END-->

<p><strong>Contextual Background:</strong>  </p>

<p>The study is grounded in the public health context of newborn screening (NBS) in the United States, specifically evaluating how genomic sequencing could expand detection of actionable pediatric-onset conditions. It builds on existing NBS frameworks and addresses policy, ethical, and clinical decision-making challenges in implementing genome-scale sequencing for healthy newborns.</p>

<h2>General Summary of the Paper</h2>

<p>This paper introduces and validates the Age-based Semiquantitative Metric (ASQM), a framework for assessing clinical actionability of gene–disease pairs in the context of newborn genomic screening. The ASQM expands a previously developed semiquantitative metric by integrating age-of-onset and age-at-intervention, categorizing conditions into four groups based on actionability and timing. The study applied the ASQM to 822 curated gene–disease pairs, compared classifications with the Recommended Uniform Screening Panel (RUSP) and the BabySeq project, and demonstrated strong concordance with high-actionability conditions. The framework provides a structured approach for deciding which genomic findings should be returned in newborn screening and could inform policy and parental decision-making.</p>

<h2>Eligibility</h2>

<p>Eligible for inclusion: <strong>Yes</strong>  </p>

<p>The paper explicitly defines clinical actionability, operationalizes it through a standardized scoring system, and identifies systematic features directly tied to the authors’ conceptualization of actionability.</p>

<h2>How Actionability is Understood</h2>

<p>The authors define actionability through five explicit criteria: severity, likelihood (penetrance), efficacy of intervention, acceptability of intervention, and knowledge base of the gene–disease association, all adapted for newborn and pediatric contexts.</p>

<blockquote>
  <p>“Each gene–disease pair was scored (0–3 points) on 5 criteria: severity… likelihood… efficacy… acceptability… knowledge base…” (p. 69–70)  </p>
</blockquote>

<blockquote>
  <p>“Gene–disease pairs were placed into… pediatric conditions with high actionability… pediatric conditions with low or no actionability… adult conditions with high actionability… adult conditions with low or no actionability.” (p. 69)</p>
</blockquote>

<h2>What Makes Something Actionable</h2>

<ul>
<li><p>High severity of potential outcome  </p></li>
<li><p>High likelihood of disease manifestation  </p></li>
<li><p>Highly effective interventions available  </p></li>
<li><p>Interventions are acceptable in terms of burden and risk  </p></li>
<li><p>Strong knowledge base and clinical consensus on gene–disease relationship</p></li>
</ul>

<h2>How Actionability is Achieved / Operationalized</h2>

<ul>
<li><p><strong>Framework/Approach Name:</strong> Age-based Semiquantitative Metric (ASQM)  </p></li>
<li><p><strong>Methods/Levers:</strong> Structured scoring (0–3) for five actionability criteria; consensus review by multidisciplinary committee  </p></li>
<li><p><strong>Operational Steps / Workflow:</strong> Literature curation → preliminary scoring → consensus meetings → categorization into 4 groups  </p></li>
<li><p><strong>Data &amp; Measures:</strong> Severity, penetrance, intervention efficacy, intervention acceptability, knowledge base; age-of-onset and age-at-intervention data  </p></li>
<li><p><strong>Implementation Context:</strong> Newborn genomic screening; policy and parental decision-making  </p></li>
</ul>

<blockquote>
  <p>“The ASQM allows a priori categorization… to facilitate decision-making about incorporating genomic sequencing into the care of newborns.” (p. 69)  </p>
</blockquote>

<blockquote>
  <p>“Gene–disease pairs… placed into 1 of 4 categories…” (p. 69)</p>
</blockquote>

<h2>Dimensions and Attributes of Actionability (Authors’ Perspective)</h2>

<ul>
<li><p><strong>CL (Clarity):</strong> Yes – explicit scoring rubric with defined terms (p. 70)  </p></li>
<li><p><strong>CR (Contextual Relevance):</strong> Yes – pediatric onset and intervention timing central to classification (p. 69)  </p></li>
<li><p><strong>FE (Feasibility):</strong> Yes – considers intervention efficacy and acceptability (p. 70)  </p></li>
<li><p><strong>TI (Timeliness):</strong> Partial – age-of-onset and age-at-intervention incorporated (p. 69)  </p></li>
<li><p><strong>EX (Explainability):</strong> Yes – transparent scoring and rationale for classification (p. 70, Fig. 1B)  </p></li>
<li><p><strong>GA (Goal Alignment):</strong> Partial – implicit in alignment with NBS goals  </p></li>
<li><p><strong>Other Dimensions Named by Authors:</strong> Knowledge base strength; ethical principle of preserving future autonomy for children</p></li>
</ul>

<h2>Theoretical or Conceptual Foundations</h2>

<ul>
<li><p>Builds on prior Semiquantitative Metric (Berg et al., 2016)  </p></li>
<li><p>Aligns with public health screening principles (Wilson and Jungner, updated for genomics)  </p></li>
<li><p>Compares to RUSP and BabySeq frameworks</p></li>
</ul>

<h2>Indicators or Metrics for Actionability</h2>

<ul>
<li><p>Total ASQM score (0–15) across five criteria  </p></li>
<li><p>Cut-offs for automatic category assignment (≥12 for high actionability, &lt;9 for low)</p></li>
</ul>

<h2>Barriers and Enablers to Actionability</h2>

<ul>
<li><p><strong>Barriers:</strong> Lack of effective interventions, insufficient knowledge base, controversial evidence  </p></li>
<li><p><strong>Enablers:</strong> Strong clinical evidence, existing practice guidelines, early intervention potential</p></li>
</ul>

<h2>Relation to Existing Literature</h2>

<p>Positions ASQM as a more integrated and age-aware framework compared to BabySeq’s validity/onset/penetrance model and validates it against RUSP’s established high-actionability conditions.</p>

<h2>Summary</h2>

<p>Milko et al. (2019) present the ASQM, an evidence-based, age-sensitive framework for scoring and classifying the actionability of genetic conditions in newborn screening. Incorporating five explicit criteria—severity, likelihood, efficacy, acceptability, and knowledge base—alongside onset and intervention timing, the ASQM categorizes conditions into four groups to guide disclosure decisions. Applied to 822 gene–disease pairs, the ASQM demonstrated strong alignment with RUSP’s core actionable conditions and provided nuanced differentiation for borderline cases. The framework operationalizes actionability with clear metrics and consensus processes, offering a scalable and transparent tool for integrating genome-scale sequencing into newborn screening programs while balancing ethical considerations.</p>

<h2>Scores</h2>

<ul>
<li><p><strong>Overall Relevance Score:</strong> 95 – Provides explicit, multidimensional definition of actionability, systematic feature set, and clear conceptual grounding.  </p></li>
<li><p><strong>Operationalization Score:</strong> 90 – Offers fully articulated scoring system, workflow, and validation, though some criteria for timeliness and goal alignment are implicit.</p></li>
</ul>

<h2>Supporting Quotes from the Paper</h2>

<ul>
<li><p>“[Each gene–disease pair was scored… on 5 criteria: severity… likelihood… efficacy… acceptability… knowledge base.]” (p. 69–70)  </p></li>
<li><p>“[Gene–disease pairs were placed into… 4 categories… based on final ASQM score, age of onset/actionability, and consensus review.]” (p. 69)  </p></li>
<li><p>“[Lack of effective intervention and/or insufficient knowledge… common reasons… not meet criteria for disclosure.]” (p. 71)  </p></li>
<li><p>“[Validated our framework against the… RUSP… high ASQM scores assigned to most RUSP conditions…]” (p. 73)</p></li>
</ul>

<h2>Actionability References to Other Papers</h2>

<ul>
<li><p>Berg et al., 2016 – Semiquantitative Metric for Evaluating Clinical Actionability  </p></li>
<li><p>Wilson &amp; Jungner screening criteria updates (Andermann et al., 2008)  </p></li>
<li><p>Ceyhan-Birsoy et al., 2017 – BabySeq curated gene list  </p></li>
<li><p>RUSP methodology references (Kemper et al., 2014)</p></li>
</ul>
